Abstract
Mebhydrolin napadisylate is an antihistamine marketed in Australia as Fabahistin, and as an ingredient of Fabahistin Plus. Since June, 1973, 11 Australian reports associating this drug with either agranulocytosis or neutropenia have been received by the Adverse Drug Reactions Advisory Committee. In seven of these reports, mebhydrolin napadisylate was the only suspected drug. These reactions are probably uncommon, but the association should be borne in mind if evidence of agranulocytosis or neutropenia is found in patients taking the drug.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.